An empirical analysis of sustained advantage in the U.S. pharmaceutical industry: Impact of firm resources and capabilities

Strategic Management Journal

Volumn 20, Issue 7, 1999, Pages 637-653

  Yeoh, Poh Lin ^a   Roth, Kendall ^b  

^a BENTLEY COLLEGE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Competent capabilities; Global NCEs; Integrative capabilities; Pharmaceutical industry; Resource based view

Indexed keywords

EID: 0000659024     PISSN: 01432095     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0266(199907)20:7<637::aid-smj42>3.0.co;2-z     Document Type: Article

References (63)

1. Amit, R. and P. J. H. Schoemaker (1993). 'Strategic assets and organizational rent', Strategic Management Journal, 14(1), pp. 33-46.
2. Arthur D. Little (1989). 'Consolidation in the pharmaceutical industry will intensify', October, pp. 57-60.
3. Bagozzi, R. P. and Y. Yi (1988). 'On the evaluation of structural equation models', Journal of the Academy of Management Science, 16(1), pp. 74-94.
4. Barney, J. (1986). 'Types of competition and the theory of strategy: Toward an integrative framework', Academy of Management Review, 11(4), pp. 791-800.
5. Barney, J. (1991). 'Firm resources and sustained competitive advantage', Journal of Management, 17(1), pp. 99-120.
6. Bentler, P. M. (1989). EQS: Structural Equations Program Manual. BMDP Statistical Software, Los Angeles, CA.
7. Bentler, P. M. and D. G. Bonnett (1980). 'Significance tests and goodness of fit in analysis of covariance structures', Psychological Bulletin, 88, pp. 588-606.
8. Blau, P. M. (1970). 'A formal theory of differentiation in organizations', American Sociological Review, 35(April), pp. 201-218.
9. Burgelman, R. and M. A. Maidique (1988). Strategic Management of Technology and Innovation. Irwin, Homewood, IL.
10. Capon, N., J. U. Farley and D. R. Lehmann (1992). 'Profiles of product innovators among large U.S. manufacturers', Management Science, 38(2), pp. 157-169.
11. Capon, N. and R. Glazer (1987). 'Marketing and technology: A strategic coalignment', Journal of Marketing, 51, pp. 1-14.
12. Castanias, R. and C. E. Helfat (1991). 'Managerial resources and rents', Journal of Management, 17(1), pp. 155-171.
13. Caves, R. E. (1982). Multinational Enterprise and Economic Analysis. Cambridge University Press, Cambridge, U.K.
14. Caves, R. E., M. D. Whinston and M. A. Hurwitz (1991). 'Patent expiration, entry, and competition in the U.S. pharmaceutical industry', Brookings Papers, pp. 1-66.
15. Cohen, W. M. and D. A. Levinthal (1989). 'Innovation and learning: The two faces of R&D', Economic Journal, 99, pp. 569-596.
16. Collis, D. J. (1994). 'How valuable are organizational capabilities?' Strategic Management Journal, Winter Special Issue, 15, pp. 143-152.
17. Cool, K. and D. E. Schendel (1987). 'Strategic group formulation and performance: The case of the U.S. pharmaceutical industry, 1963-1982', Management Science, 33(9), pp. 1102-1124.
18. Cooper, R. G. and E. J. Kleinschmidt (1990). 'New product success factors: A comparison of kills versus success and failures', R&D Management, 20(1), pp. 168-184.
19. Di Masi, J., M. A. Seibring and L. Lasagna (1994). 'New drug development in the United States from 1963 to 1992', Clinical Pharmacology and Therapeutics, June, pp. 609-622.
20. Dierickx, I. and K. Cool (1989). 'Asset stock accumulation and sustainability of competitive advantage', Management Science, 35, pp. 1504-1511.
21. Ettlie, J. E. (1983). 'Organizational policy and innovation among suppliers to the food processing industry', Academy of Management Journal, 26, pp. 27-44.
22. Ettlie, J. E. and A. H. Rubenstein (1987). 'Firm size and product innovation', Journal of Product Innovation Management, 4, pp. 89-108.
23. Fiegenbaum, A., D. Sudharsan and H. Thomas (1990). 'Strategic time periods and strategic groups research: Concepts and an empirical evidence', Journal of Management Studies, 27(2), pp. 133-148.
24. Financial World (1989). 'Pharmaceuticals', 30 May, pp. 54-77.
25. Foss, N. J. (1996). 'Knowledge-based approaches to the theory of the firm: Some critical comments', Organization Science, 7(5), pp. 470-476.
26. Ghemawat, P. (1986). 'Sustainable advantage', Harvard Business Review, 86(5), pp. 53-58.
27. Ginsberg, A. (1988). 'Measuring and modeling changes in strategy: Theoretical foundations and empirical directions', Strategic Management Journal, 9(6), pp. 559-575.
28. Gold, B. (1987). 'Approaches to accelerating product and process development', Journal of Product Innovation Management, 4, pp. 81-88.
29. Grant, R. B. (1991). 'A resource-based theory of competitive advantage: Implications for strategy formulation', California Management Review, 33(3), pp. 114-135.
30. Graves, S. B. and N. S. Langowitz (1993). 'Innovative productivity and returns to scale in the pharmaceutical industry', Strategic Management Journal, 14(8), pp. 593-605.
31. Hambrick, D. C. and I. C. MacMillan (1985). 'Efficiency of product R&D in business units: The role of strategic context', Academy of Management Journal, 28(September), pp. 527-547.
32. Hamel, G. and C. K. Prahalad (1990). 'The core competence of the corporation', Harvard Business Review, 68(3), pp. 79-91.
33. Hamel, G. and C. K. Prahalad (1993). 'Strategy as stretch and leverage', Harvard Business Review, 71(2), pp. 75-84.
34. Henderson, R. and I. Cockburn (1994). 'Measuring competence?: Exploring firm effects in pharmaceutical research', Strategic Management Journal, Winter Special Issue, 15, pp. 63-84.
35. Hofer, C. W. and D. Schendel (1978). Strategy Formulation: Analytical Concepts. West, St Paul, MN.
36. ITC (International Trade Commission) (1991). Global Competitiveness of U.S. Advanced-Technology Manufacturing Industries: Pharmaceuticals, report to the Committee on Finance, U.S. Senate, U.S. International Trade Commission, Washington DC.
37. Kogut, B. and U. Zander (1992). 'Knowledge of the firm, combinative capabilities, and the replication of technology', Organization Science, 3(3), pp. 502-518.
38. Lado, A., N. G. Boyd and P. Wright (1992). 'A competency-based model of sustainable competitive advantage: Toward a conceptual integration', Journal of Management, 18(1), pp. 77-91.
39. Leonard-Barton, D. (1992). 'Core capabilities and core rigidities: A paradox in managing new product development', Strategic Management Journal, Summer Special Issue, 13, pp. 111-125.
40. Mahoney, J. and J. R. Pandian (1992). 'The resource-based view within the conversation of strategic management', Strategic Management Journal, 13(5), pp. 363-380.
41. Maidique, M. A. and R. A. Hayes (1984). 'The art of high technology management', Sloan Management Review, 26(2), pp. 17-31.
42. Maijoor, S. and A. van Witteloostuijn (1996). 'An empirical test of the resource-based theory: Strategic regulation in the Dutch audit industry', Strategic Management Journal, 17(7), pp. 549-569.
43. Mansfield, E., M. Schwartz and S. Wagner (1981). 'Imitation costs and patents: An empirical study', Economic Journal, 91(December), pp. 907-918.
44. Nelson, R. and S. Winter (1982). An Evolutionary Theory of Economic Change. Harvard University Press, Cambridge, MA.
45. Omta, S. W. F., L. M. Bouter and J. M. L. van Engelen (1994). 'Managing industrial pharmaceutical R&D: A comparative study of management control and innovative effectiveness in European and Anglo-American companies', R&D Management, 24(4), pp. 303-315.
46. Penrose, E. T. (1959). The Theory of the Growth of the Firm. Wiley, New York.
47. Peteraf, M. A. (1993). 'The cornerstones of competitive advantage: A resource-based view', Strategic Management Journal, 14(3), pp. 179-191.
48. Porter, M. (1980). Competitive Strategy. Free Press, New York.
49. Porter, M. (1983). 'The technological dimension of competitive strategy'. In R. Rosenbloom (ed.), Research on Technological Innovation, Management and Policy. JAI Press, Greenwich, CT, pp. 1-33.
50. Prescott, E. and M. Visscher (1977). 'Sequential location among firms with foresight', Bell Journal of Economics, 8, pp. 378-393.
51. Roberts, E. B. (1989). 'Managing technological innovation in the pharmaceutical industry', Research Technology Management, July-August, pp. 34-41.
52. Robinson, W. T. and C. Fornell (1985). 'Sources of market pioneering advantages in consumer goods industries', Journal of Marketing Research, 22(August), pp. 305-317.
53. Sapienza, A. (1993). 'Assessing the R&D capability of the Japanese pharmaceutical industry', R&D Management, 23(1), pp. 3-16.
54. Scherer, F. M. (1980). Industrial Market Structure and Economic Performance. Houghton Mifflin, Boston, MA.
55. Schmalensee, R. (1978). 'Entry deterrence in the ready to eat breakfast cereal industry', Bell Journal of Economics, 9(Autumn), pp. 305-327.
56. Schmalensee, R. (1982). 'Product differentiation advantages of pioneering brands', American Economic Review, 72(June), pp. 349-365.
57. Sheck, L., C. Cox, H. Davis, G. Trimble, W. Wardell and R. Hansen (1984). 'Success rates in the U.S. drug development system', Clinical Pharmacology and Therapeutics, 36(5), pp. 574-583.
58. SRI International (1989). 'Pharmaceutical: Industry challenges', Report no. 775, pp. 1-28.
59. Taggart, J. (1993). The World Pharmaceutical Industry. Routledge, London.
60. Teece, D. (1987). 'Profiting from technological innovation: Implications for integration, collaboration, licensing, and public policy'. In: D. Teece (ed.), The Competitive Challenge: Strategies for Industrial Innovation and Renewal. Ballinger, Cambridge, MA, 185-219.
61. Tushman, M. L. and P. Anderson (1986). 'Technological discontinuities and organization environments', Administrative Science Quarterly, 31, pp. 439-465.
62. Vernon, J. M. and P. Gusen (1974). 'Technical change and firm size: The pharmaceutical industry', Review of Economics and Statistics, 56, pp. 294-302.
63. Zirger, B. J. and M. A. Maidique (1990). 'A model of new product development: An empirical test', Management Science, 36(7), pp. 867-883.